Drugs / AGS15E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01963052 | Nov 2013 → Jul 2019 | urothelial carcinoma | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS15E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01963052 ↗ |
| Action | Deplete | “delivers the cytotoxic drug monomethyl auristatin E to cells expressing SLITRK6” PMID 37861407 ↗ Jan 2024 |
| Modality | Other / unclassified | “AGS15E is an investigational ADC” PMID 37861407 ↗ Jan 2024 |
| Route | Intravenous | “AGS15E was administered intravenously at six levels” PMID 37861407 ↗ Jan 2024 |